A Short History

Sanofi Pasteur in Canada owes its foundation to the pioneering vision of Dr. John G. FitzGerald (1882-1940), a graduate of the University of Toronto Medical School. After studying bacteriology at the Pasteur Institute and elsewhere, FitzGerald was appointed professor of hygiene at the University of Toronto in 1913.

FitzGerald's goal was to provide life-saving public health products in Canada at a price that was within the reach of everyone. At the time, diphtheria was the number one killer of children, but diphtheria antitoxin production required horses. Using his wife's inheritance, FitzGerald built a backyard laboratory and stable, bought horses and began preparing the antitoxin. Encouraged by his efforts, and sales to the Ontario government, on May 1, 1914, the University of Toronto officially established the Antitoxin Laboratories.  

Connaught Laboratories opened

A severe shortage of tetanus antitoxin during World War I prompted the donation of a large farm property north of Toronto, along with facilities for antitoxin production. On October 25, 1917, FitzGerald's expanded enterprise was officially christened the Connaught Antitoxin Laboratories and University Farm, named after the Duke of Connaught, Canada's wartime governor general.

In the 1920s, Connaught underwent rapid growth after the discovery of insulin at the university and the development of large-scale insulin production methods. Connaught Labs was also the first to conduct field trials of diphtheria toxoid, firmly establishing its effectiveness as an immunizing agent.

Other important products pioneered in the 1930s included fresh-strain pertussis vaccine and heparin, a blood anticoagulant.

During World War II, Connaught produced dried blood serum for the treatment of shock among soldiers. The most dramatic project was the production of penicillin in time for D-Day. On the home front, Connaught developed combined antigens that provided protection against diphtheria, pertussis and tetanus in one shot.

Contribution to polio vaccine

In the 1950s, Connaught scientists enabled Jonas Salk to develop a safe inactivated polio vaccine. Connaught's new synthetic Medium 199 provided a safe base, while the "Toronto Method" of producing rocked-bottle cultures allowed enough poliovirus fluids to be produced for an unprecedented US field trial of Salk's vaccine in 1954.

After introducing DPT-Polio vaccine in 1959, Connaught launched an intensive effort to produce the first trivalent Sabin live oral polio vaccine. In addition to new vaccines against influenza and measles, a freeze-dried smallpox vaccine was developed in the 1960s, which, along with Connaught's other contributions, played a major role in the global eradication of smallpox.

 

Connaught expands

In 1972, the University of Toronto sold Connaught to the Canadian Development Corporation, transforming the labs into a profit-driven company. In 1978, the acquisition of a vaccine manufacturing facility in Swiftwater, PA, facilitated Connaught's expansion into the United States biologicals market.

In 1989, expansion into the global vaccine market accelerated when Institut Mérieux of France assumed control of Connaught, adding to its existing alliance with the Pasteur Institute to create Pasteur Mérieux Connaught (PMC). A decade later, PMC's parent company, Rhone-Poulenc, merged with Hoeschst of Germany to create Aventis. PMC thus became Aventis Pasteur, its Connaught Campus in Toronto officially known as Aventis Pasteur Limited.  In 2004, Aventis was acquired by Sanofi-Synthelabo to form the sanofi aventis Group wherein Aventis Pasteur officially became sanofi pasteur.  The Connaught campus in Toronto is now Sanofi Pasteur Limited.

Dr. FitzGerald had a very strong sense of responsibility towards all Canadians. His commitment, leadership and legacy would later benefit people around the world. Sanofi Pasteur is proud to continue in his footsteps.